Last A$0.10 AUD
Change Today +0.001 / 1.05%
Volume 5.0K
CZD On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 6:02 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

calzada ltd (CZD) Snapshot

Open
A$0.10
Previous Close
A$0.10
Day High
A$0.10
Day Low
A$0.10
52 Week High
03/21/14 - A$0.16
52 Week Low
11/28/13 - A$0.07
Market Cap
40.2M
Average Volume 10 Days
130.5K
EPS TTM
A$-0.0068
Shares Outstanding
418.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CALZADA LTD (CZD)

Related News

No related news articles were found.

calzada ltd (CZD) Related Businessweek News

No Related Businessweek News Found

calzada ltd (CZD) Details

Calzada Limited, through its subsidiaries, operates as a biotechnology company in Australia. The company develops NovoSorb, a biodegradable polymer technology that is designed to be used in medical devices and tissue engineering scaffolds for reconstructive surgery and repair in a range of fields, including wounds, burns, cardiovascular, orthopaedic, periodontal, cartilage, and drug delivery. It also owns AOD9604, a small 16 amino acid peptide modeled for human growth hormone, which has applications in the treatment of obesity, bone, cartilage, and muscle diseases and repair. Calzada Limited is based in Port Melbourne, Australia.

4 Employees
Last Reported Date: 08/25/14

calzada ltd (CZD) Top Compensated Officers

Chief Financial Officer and Company Secretary
Total Annual Compensation: A$181.1K
Chief Executive Officer of PolyNovo Biomateri...
Total Annual Compensation: A$235.0K
Chief Executive Officer of Metabolic Pharmace...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

calzada ltd (CZD) Key Developments

Calzada Limited Announces Appointment of Paul Brennan as Chief Executive Officer

Calzada Ltd. announced the appointment of Mr. Paul Brennan as Chief Executive Officer. Since 2008 Paul has been the Marketing Director Australia and New Zealand and Sales Director New Zealand of Smith and Nephew. Smith and Nephew are a global leading wound care, orthopedic implant, endoscopy and biologic manufacturer.

Calzada Limited Proposes Amendments to Constitution

Calzada Limited proposed amendments to constitution of the company. The company proposed that the constitution related to alteration of share capital, reductions of capital, postponement and adjournment of meeting, ancillary powers, buy-backs, admission to general meetings, direct votes, retirement benefits, written resolutions, times for inspection and payment.

Calzada Limited, Annual General Meeting, Nov 17, 2014

Calzada Limited, Annual General Meeting, Nov 17, 2014., at 10:00 E. Australia Standard Time. Location: Unit 2, 320 Lorimer Street. Agenda: To consider financial statements; to consider other business; to consider election and re-election of directors; to consider remuneration report; to consider employee share option plans; to consider issue of options to certain directors; to consider change of name; and to consider amendment to constitution.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CZD:AU A$0.10 AUD +0.001

CZD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CZD.
View Industry Companies
 

Industry Analysis

CZD

Industry Average

Valuation CZD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 430.5x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 375.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CALZADA LTD, please visit www.metabolic.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.